THE ROLE OF GLP-1 RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES MELLITUS AND OBESITY
Keywords:
GLP-1 receptor agonists, obesity, type 2 diabetes mellitus, semaglutide, liraglutide, tirzepatide, glycemic control, weight loss.Abstract
Obesity and type 2 diabetes mellitus (T2DM) are among the most prevalent chronic diseases worldwide and represent major public health challenges. The growing prevalence of these conditions has increased the demand for effective therapeutic strategies that address both glycemic control and excess body weight. Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a promising class of medications due to their ability to improve glucose metabolism, reduce appetite, and promote weight loss. This article reviews the physiological mechanisms, clinical effectiveness, therapeutic benefits, and adverse effects of GLP-1 receptor agonists in the management of diabetes mellitus and obesity. Current evidence indicates that agents such as liraglutide, semaglutide, and tirzepatide significantly improve glycemic parameters, decrease body weight, and reduce cardiovascular risk. These findings support the increasing role of GLP-1 receptor agonists as an important component of modern metabolic disease management.
References
Drucker DJ. The biology of incretin hormones. Cell Metabolism. 2018.
Holst JJ. The physiology of glucagon-like peptide-1. Physiological Reviews. 2019.
American Diabetes Association. Standards of Care in Diabetes. 2025.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021.
Davies MJ, et al. Management of hyperglycemia in type 2 diabetes. Diabetes Care. 2022.
Nauck MA, Meier JJ. Incretin hormones and diabetes. Diabetologia. 2019.
Ryan DH, Kahan S. Guideline recommendations for obesity management. Medical Clinics of North America. 2021.
Garvey WT, et al. American Association of Clinical Endocrinology clinical practice guidelines. Endocrine Practice. 2022.
Jastreboff AM, et al. Tirzepatide once weekly for obesity treatment. New England Journal of Medicine. 2022.
Lean MEJ, et al. Weight management and diabetes remission. Lancet. 2019.
Marso SP, et al. Liraglutide and cardiovascular outcomes. New England Journal of Medicine. 2016.
Gerstein HC, et al. Dulaglutide and cardiovascular outcomes. Lancet. 2019.
Perreault L, et al. Obesity and metabolic disease management. Diabetes Care. 2023.
World Health Organization. Obesity and overweight fact sheets. WHO Publications.





